View Exam | PowerPak

1. Which of the following statements regarding the results of clinical studies on the use of non-vitamin K oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation is INCORRECT?

A. All NOACs were noninferior to warfarin regarding stroke or systemic embolism prevention. B. All NOACs were significantly better than warfarin for hemorrhagic stroke prevention. C. Only apixaban was associated with significantly lower all-cause mortality than warfarin. D. Rivaroxaban and apixaban were associated with significantly better prevention of ischemic stroke than warfarin.

2. Which of the following non-vitamin K oral anticoagulants demonstrated significantly lower bleeding events in the North American studies of patients having knee replacement surgery?

A. Apixaban B. Dabigatran C. Edoxaban D. Rivaroxaban

3. Which of the following is NOT a major difference between non-vitamin K oral anticoagulants and warfarin?

A. Time-to-onset and offset of action B. Size of therapeutic window C. Requirement for regular international normalized ratio measurements D. Drug-food interactions

4. Which of the following statements regarding the use of non-vitamin K oral anticoagulants (NOACs) in practice is CORRECT?

A. All 4 NOACs inhibit Factor Xa. B. All 4 NOACs are effective for the treatment of patients with venous thromboembolism (VTE). C. All 4 NOACs are approved for VTE prevention in total hip replacement surgery. D. All 4 NOACs are approved for VTE prevention in total knee replacement surgery.

5. JA is a 63-year-old male who has been taking warfarin for 2 years due a previous venous thromboembolism. He lives 60 minutes from his physician's office, so he has not been having his international normalized ratios checked at regular intervals. He is scheduled to undergo total hip replacement surgery, and his physician is asking his health insurance provider to cover a switch from warfarin to a non-vitamin K oral anticoagulant (NOAC) moving forward. Which of the following factors is LEAST IMPORTANT when determining the overall risk to benefit of switching JA from warfarin to an NOAC?

A. Clinical indication B. Efficacy and safety C. Acquisition cost alone D. Distance to clinician office

1. Which of the following statements regarding the results of clinical studies on the use of non-vitamin K oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation is INCORRECT?

2. Which of the following non-vitamin K oral anticoagulants demonstrated significantly lower bleeding events in the North American studies of patients having knee replacement surgery?

3. Which of the following is NOT a major difference between non-vitamin K oral anticoagulants and warfarin?

4. Which of the following statements regarding the use of non-vitamin K oral anticoagulants (NOACs) in practice is CORRECT?

« Return to Activity